<DOC>
	<DOCNO>NCT00179478</DOCNO>
	<brief_summary>The current study extension previous phase III CHAMPS study ( see reference ) . This study design determine immediate initiation therapy Interferon Beta-1a ( AVONEX ) first attack multiple sclerosis continue delay development attack development neurological disability 10 year period observation .</brief_summary>
	<brief_title>Long Term Study Avonex Therapy Following First Attack Multiple Sclerosis</brief_title>
	<detailed_description>The CHAMPS study determine immediate initiation interferon beta 1a therapy ( AVONEX ) immediately follow first clinical demyelinating event high risk patient ( i.e . least 2 asymptomatic white matter lesion cranial MR image &gt; 3 mm diameter ovoid ) delay development clinical definite Multiple Sclerosis ( CDMS ) ( defined second , clinically verifiable attack involve another part central nervous system ) 2 year observation significantly decrease development new enlarge white matter lesion MRI 18 month ( see reference ) . The current study long term extension cohort CHAMPS study participant . The three main aim study follow : 1 . To determine long term neurological outcome patient treat interferon beta 1a ( AVONEX ) onset first clinical demyelinating event 2 . To determine immediate initiation AVONEX therapy ( CHAMPS Avonex treatment group ) confers long term benefit compare delayed initiation therapy ( CHAMPS placebo group ) rate development CDMS , annualized relapse rate , development permanent disability MR measure disease activity progression . 3 . To determine predictor long term disease activity disability patient follow first clinical demyelinating event</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Myelitis</mesh_term>
	<mesh_term>Myelitis , Transverse</mesh_term>
	<mesh_term>Cerebellar Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Previous participation CHAMPS study Willingness enroll prior 5 year visit Willingness sign inform consent Discovery alternative neurological disorder MS cause initial neurological symptom A severe systemic disease likely mortality within 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Interferon Beta</keyword>
	<keyword>MRI</keyword>
	<keyword>Optic neuritis</keyword>
	<keyword>Transverse Myelitis</keyword>
</DOC>